Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease

Digestive and Liver Disease

Volumn 40, Issue 3, 2008, Pages 194-199

  Spadaro, L ^a   Magliocco, O ^a   Spampinato, D ^a   Piro, S ^a   Oliveri, C ^a   Alagona, C ^a   Papa, G ^a   Rabuazzo, A M ^a   Purrello, F ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Metabolic syndrome; NAFLD; PUFAs; Ultrasonography

Indexed keywords

ALANINE AMINOTRANSFERASE; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL RADIOGRAPHY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; ECHOGRAPHY; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MALE; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REMISSION; TREATMENT DURATION;

FATTY ACIDS, OMEGA-3; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN RESISTANCE; LIPOGENESIS; LIVER; MALE; MIDDLE AGED; TRANSAMINASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38749115791     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.10.003     Document Type: Article

References (33)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
2. Bugianesi E., McCullough A.J., and Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42 (2005) 987-1000
3. McCullough A.J. Pathophysiology of non-alcoholic steatohepatitis. J Clin Gastroenterol 40 (2006) S17-S29
4. Araya J., Rodrigo R., Videla L.A., Thielemann L., Orellana N., Pettinelli P., et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci 06 (2004) 635-643
5. Clarke S.D., Nonalcoholic Steatosis, and Steatohepatitis I. Molecular mechanism for Polyunsaturated fatty acid regulation of gene transcription. Am J Physiol Gastrointest Liver Physiol 281 (2001) G865-G869
6. Krey G., Braissant O., L'Horset F., Kakoven E., Perroud M., Parker M.G., et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferatorsactivated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 11 (1997) 779-791
7. Calder P.C. N-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 83 suppl (2006) 1505S-19S
8. Svegliati-Baroni G., Candelaresi C., Saccomanno S., Ferretti G., Bachetti T., Marzioni M., et al. A Model of insulin resistance and Nonalcoholic Steatohepatitis in Rats. Am J Pathol (2006) 169-173
9. Taouis M., Dagou C., Ster C., Durand G., Pinault M., and Delarue J. N-3 polyunsaturated fatty acids prevent the defect of insulin receptor signalling in muscle. Am J Physiol Endocrinol Metab 282 (2002) E664-E671
10. Capanni M., Calella F., Biagini M.R., Genie S., Raimondi L., Bedogni G., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 23 (2006) 1143-1151
11. Nettleton J.A., and Katz R. N-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. Am Diet Assoc 105 (2005) 428-440
12. Krauss R.M., Eckel R.H., Howard B., Appel L.J., Daniels S.R., Deckelbaum R.J., et al. AHA dietary guidelines: Revision 2000: a statement for Healthcare Professional from the Nutrition Committee of the American Heart Association. Circulation 102 (2000) 2284-2299
13. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., et al. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology 123 (2002) 745-750
14. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
15. McCullough A.J. Thiazolidinediones for nonalcoholic steatohepatitis. Promising but not ready for prime time. N Engl J Med 355 (2006) 2361-2363
16. Carpentier Y.A., Portois L., and Malaisse W.J. n-3 Fatty acids and the metabolic syndrome. Am J Clin Nutr 83 Suppl. (2006) 1499S-504S
17. Crespo J., Cayon A., Fernandez-Gil P., Hernandez-Guerra M., Mayorga M., Dominguez-Diez A., et al. Gene expression of tumor necrosis factor alpha and TNF receptors, p55 and p75 in non-alcoholic steatohepatitis patients. Hepatology 34 (2001) 1158-1163
18. Manco M., Marcellini M., Giannone G., and Nobili V. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am J Clin Pathol 127 (2007) 954-960
19. Lin H.Z., Yang S.Q., Chuckaree C., Kuhajda F., Ronnet G., and Diehl A.M. Metformin reverses fatty liver disease in obese, leptin deficient mice. Nat Med 6 (2000) 998-1003
20. Satapathy S.K., Garg S., Chauhan R., Sakhuja P., Malhotra V., Sharma B.C., et al. Beneficial effects of tumor necrosis factor-a inhibition by pentoxifylline on clinical, biochemical and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 99 (2004) 1946-1952
21. Lee S., Gura K.M., and Puder M. Omega-3 fatty acids and liver disease. Hepatology 45 (2007) 841-845
22. Calder P.C. Polyunsaturated fatty acids and inflammation. Biochem Soc Trans 33 (2005) 423-427
23. Skuladottir I.H., Petursdottir D.H., and Hardartottir I. The effects of omega-3-polyunsaturated fatty acids on TNF-alpha and IL-10 secretion by murine peritoneal cells in vitro. Lipids 42 (2007) 699-706
24. Virkamaki A., Ueki K., and Kahn C.R. Protein-interaction in insulin signalling and the molecular mechanisms of insulin resistance. J Clin Invest 103 (1999) 931-943
25. Combettes-Souverain M., and Issad T. Molecular basis on insulin action. Diabetes Metab 24 (1998) 477-489
26. Shimomura I., Matsuda M., Hammer R.E., Bashmakov Y., Brown M.S., and Goldstein J.L. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic an ob/ob mice. Mol Cell 6 (2000) 77-86
27. Shimomura I., Bashmakov Y., and Horton J.D. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 274 (1999) 30028-30032
28. Sekiya M., Yahagi N., Matsuzaka T., Najima Y., Nakakuki M., Nagai R., et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 38 (2003) 1529-1539
29. Ip E., Farrell G., Hall P., Robertson G., and Leclercq I. Administration of the potent PPAR alpha agonist, Wyeth 14,643 reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39 (2004) 1286-1296
30. Ip E., Farrell G.C., Robertson G., Hall P., Kirsch R., and Leclercq I. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38 (2003) 123-132
31. Sanyal A.J. AGA technical review on non-alcoholic fatty liver disease. Gastroenterology 123 (2002) 1705-1725
32. Ribeiro P.S., Cortez Pinto H., Solà S., Castro R.E., Ramalho R.M., Baptista A., et al. Hepatocyte Apoptosis, expression of death receptors, and activation of NF-κB in the liver of non-alcoholic and alcoholic Steatohepatitis patients. Am J Gastroenterol 99 (2004) 1708-1717
33. Kim H.C., Choi S.H., Shin H.W., Cheong J.Y., Lee K.W., Lee H.C., et al. Severity of ultrasonographic liver steatosis and metabolic syndrome in Korean men and women. World J Gastroenterol 11 (2005) 5314-5321